当前位置:
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2020-01-23 , DOI: 10.1038/s41408-020-0274-9 D Wang 1 , C Zeng 1 , B Xu 1 , J-H Xu 1 , J Wang 1 , L-J Jiang 1 , Q-X Wang 1 , C-R Li 1 , N Wang 1 , L Huang 1 , Y-C Zhang 1 , Y Xiao 1 , J-F Zhou 1
中文翻译:
抗CD30嵌合抗原受体T细胞疗法用于复发/难治性CD30 +淋巴瘤患者。
更新日期:2020-01-24
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2020-01-23 , DOI: 10.1038/s41408-020-0274-9 D Wang 1 , C Zeng 1 , B Xu 1 , J-H Xu 1 , J Wang 1 , L-J Jiang 1 , Q-X Wang 1 , C-R Li 1 , N Wang 1 , L Huang 1 , Y-C Zhang 1 , Y Xiao 1 , J-F Zhou 1
Affiliation
中文翻译:
抗CD30嵌合抗原受体T细胞疗法用于复发/难治性CD30 +淋巴瘤患者。